INCY News and Press, Incyte Corporation From 10/26/20

Incyte Announces Health Canada Acceptance of the New Drug Submission for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma Canada NewsWire MONTREAL, Oct. 26, 2020 MONTREAL , Oct. 26, 2020 /CNW/ - Incyte (Nasdaq: INCY) today announced that Health...

FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 22, 2020 – USA News Group – It’s been a year and a half since the US Food and Drug Administration approved the first targeted immunotherapy in the treatment...

Eli Lilly ([[LLY]] -0.5%) and its collaborating partner Incyte ([[INCY]] +0.1%) have announced additional efficacy and safety data from Adaptive COVID-19 treatment trial (ACTT-2), demonstrating baricitinib in combination with remdesivir reduced recovery time and improved clinical outcome...

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million. Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical-stage assets and one preclinical platform in China. Zai Lab of Shanghai has dosed the first patient in...

Following up on their announcement on September 14, Eli Lilly ([[LLY]] +1.9%) and licensor Incyte ([[INCY]] +1.3%) announce additional data from an NIAID-sponsored study, ACTT-2, evaluating the combination of Olumiant (baricitinib) and Gilead Sciences' ([[GILD]] +0.5%) Veklury (remdesivir) co...

Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen Further results from NIAID-sponsored ACTT-2 Trial Presented Today PR Newswire INDIANAPOLIS, Oct. 8, 2020 INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ --&...

Kodiak Sciences reports initiation of Phase 3 trial of KSI-301. Incyte announces peptide-centric strategic collaboration with Nimble. AMAG receives a setback as the FDA rejects Makena. For further details see: Kodiak Initiates Phase 3 Trial, And Other News: The Good, Bad...

Incyte ([[INCY]] +2.7%) has entered into a collaboration with privately held Nimble Therapeutics to discover peptide therapies across various disease areas.The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, coupled wit...

Nimble Therapeutics Inc. today announced the company has entered into a strategic collaboration with Incyte (NASDAQ: INCY) to discover first-in-class peptide therapies across various disease areas. “This is an important collaboration for both companies to discover novel pepti...

The first participant has been dosed in a China-based Phase 3 clinical trial, PODIUM-304, evaluating Zai Lab Limited (ZLAB) and Incyte's (INCY) PD-1 inhibitor retifanlimab, combined with platinum-based chemo, in treatment-naïve patients with metastatic non-small cell lung cancer ((NSCLC)...